Wellington Management Group LLP Has $323.80 Million Position in Glaukos Co. (NYSE:GKOS)

Wellington Management Group LLP lowered its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 1.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,159,539 shares of the medical instruments supplier's stock after selling 24,227 shares during the quarter. Wellington Management Group LLP owned approximately 3.82% of Glaukos worth $323,801,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. William Blair Investment Management LLC acquired a new stake in shares of Glaukos during the fourth quarter worth $121,390,000. Norges Bank purchased a new stake in Glaukos during the fourth quarter worth approximately $84,490,000. Raymond James Financial Inc. purchased a new position in Glaukos in the fourth quarter valued at about $16,910,000. Vanguard Group Inc. raised its holdings in shares of Glaukos by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after buying an additional 101,838 shares during the period. Finally, State Street Corp raised its stake in shares of Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after purchasing an additional 98,109 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of Glaukos stock traded down $3.38 during trading on Friday, hitting $83.62. The stock had a trading volume of 1,715,189 shares, compared to its average volume of 616,738. The business has a fifty day moving average of $123.88 and a two-hundred day moving average of $134.70. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The firm has a market cap of $4.73 billion, a P/E ratio of -29.14 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Remove Ads

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GKOS. Stifel Nicolaus lifted their target price on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Piper Sandler reissued an "overweight" rating and set a $180.00 target price (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Wells Fargo & Company boosted their price objective on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Mizuho raised shares of Glaukos from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Finally, Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and raised their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.